Delving into the Latest Updates on Human Allogeneic mesenchymal bone marrow derived stem cells(Clinica Santa Clarita) with Synapse

Overview

Basic Info

Drug Type

Mesenchymal stem cell therapy

Synonyms-

Target-

Action-

Mechanism-

Therapeutic Areas-

Active Indication-

Inactive Indication-

Originator Organization

Clinica Santa Clarita, S.C.

Active Organization-

Inactive Organization-

License Organization-

Drug Highest Phase-

First Approval Date-

Regulation-

The aim of this study is to assess the safety of Stemedica's mesenchymal stem cells in patients with knee osteoarthritis. The route of administration is intraarticular. Safety will be evaluated by AE/SAE incidence and administration tolerance. The subjects will undergo follow-up for 52 weeks. The target population is subjects with knee osteoarthritis (grade II-III in Kellgren-Lawrence scale).

Start Date01 Aug 2019

Sponsor / Collaborator

Clinica Santa Clarita, S.C.

100 Clinical Results associated with Human Allogeneic mesenchymal bone marrow derived stem cells(Clinica Santa Clarita)

Login to view more data

100 Translational Medicine associated with Human Allogeneic mesenchymal bone marrow derived stem cells(Clinica Santa Clarita)

Login to view more data

100 Patents (Medical) associated with Human Allogeneic mesenchymal bone marrow derived stem cells(Clinica Santa Clarita)

Login to view more data

100 Deals associated with Human Allogeneic mesenchymal bone marrow derived stem cells(Clinica Santa Clarita)

Login to view more data